Drugs / NovoMix 30
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02587741 | Jul 2015 → Jul 2023 | diabetic retinopathy | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00151697 | May 2005 → ? | type 2 diabetes mellitus | Rijnstate Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00776607 | Apr 2007 → Apr 2011 | latent autoimmune diabetes in adults | Abertawe Bro Morgannwg University NHS Trust | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT04226105 Comparator | Jan → Sep 2020 | type 2 diabetes mellitus | Geropharm | Unknown | No outcome recorded |
| Phase 4 | NCT02219750 Comparator | Aug 2013 → Aug 2015 | type 2 diabetes mellitus | Mackay Memorial Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Novomix30 | “preprandial NovoMix 30” NCT02219750 ↗ |
| Known as | NovoMix 30 FlexPen | “Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients” NCT04226105 ↗ |
| Modality | Protein / enzyme biologic | “twice daily administration of a mixture of short- and longacting insulin” NCT00151697 ↗ |